Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1971 1
1974 1
1975 1
1976 2
1977 1
1979 1
1981 1
1985 3
1986 4
1988 2
1989 2
1990 9
1991 6
1992 6
1993 6
1994 9
1995 8
1996 10
1997 12
1998 21
1999 11
2000 13
2001 8
2002 6
2003 9
2004 8
2005 19
2006 11
2007 11
2008 17
2009 23
2010 19
2011 26
2012 20
2013 20
2014 22
2015 20
2016 28
2017 33
2018 19
2019 27
2020 32
2021 22
2022 28
2023 16
2024 27
2025 35

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

590 results

Results by year

Filters applied: . Clear all
Page 1
The stabilizing mechanism of cadmium in contaminated soil using green synthesized iron oxide nanoparticles under long-term incubation.
Lin J, He F, Su B, Sun M, Owens G, Chen Z. Lin J, et al. J Hazard Mater. 2019 Nov 5;379:120832. doi: 10.1016/j.jhazmat.2019.120832. Epub 2019 Jun 27. J Hazard Mater. 2019. PMID: 31276925
Here green synthesized iron oxide nanoparticles (GION) were applied to stabilize cadmium (Cd) in a contaminated soil. GION not only stabilized soil Cd, but also improved soil properties within one year of incubation. ...The application of GION also strongly a …
Here green synthesized iron oxide nanoparticles (GION) were applied to stabilize cadmium (Cd) in a contaminated soil. GION not …
Fluid Status Vulnerability in Older Adults.
Purvis S, Gion T. Purvis S, et al. J Infus Nurs. 2024 Jan-Feb 01;47(1):49-53. doi: 10.1097/NAN.0000000000000534. J Infus Nurs. 2024. PMID: 38211615 Review.
Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis.
Ravaggi A, Bergamaschi C, Galbiati C, Zanotti L, Fabricio ASC, Gion M, Cappelletto E, Leon AE, Gennarelli M, Romagnolo C, Ciravolo G, Calza S, Bignotti E, Odicino F. Ravaggi A, et al. Biomedicines. 2024 Oct 19;12(10):2393. doi: 10.3390/biomedicines12102393. Biomedicines. 2024. PMID: 39457705 Free PMC article.
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, Martínez-Bueno A, Ruiz-Borrego M, Llabrés E, Taberner MT, de Laurentiis M, García-Vicente S, Guerrero JA, Boix O, Rodríguez-Morató J, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A; ATRACTIB Trial Investigators. Gion M, et al. Nat Med. 2025 Aug;31(8):2746-2754. doi: 10.1038/s41591-025-03734-3. Epub 2025 Jun 4. Nat Med. 2025. PMID: 40467896 Free PMC article. Clinical Trial.
Delirium in the brain-injured patient.
Gion T, Leclaire-Thoma A. Gion T, et al. Rehabil Nurs. 2014 Sep-Oct;39(5):232-9. doi: 10.1002/rnj.128. Epub 2013 Oct 29. Rehabil Nurs. 2014. PMID: 24170310 Review.
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Nat Med. 2024 Dec;30(12):3780. doi: 10.1038/s41591-024-03349-0. Nat Med. 2024. PMID: 39653780 Free PMC article. No abstract available.
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.
Llombart-Cussac A, Pérez-García J, Brasó-Maristany F, Paré L, Villacampa G, Gion M, Schmid P, Colleoni M, Borrego MR, Galván P, Parker JS, Buckingham W, Perou CM, Villagrasa P, Guerrero JA, Sampayo-Cordero M, Mancino M, Prat A, Cortés J. Llombart-Cussac A, et al. Clin Cancer Res. 2024 Sep 13;30(18):4123-4130. doi: 10.1158/1078-0432.CCR-24-0464. Clin Cancer Res. 2024. PMID: 38995291 Free PMC article. Clinical Trial.
590 results